Replies to post #26995 on RespireRx Pharmaceuticals Inc (RSPI)

[bladerunner1717]

Quintiles leads the CRO market.


The Top 10 Contract Research Organizations

Positioning, performance and SWOT analyses

Dear Colleague,

Cost containment and regulatory pressures within the pharma industry are driving R&D outsourcing across the globe. Clinical obstacles to approval have become more significant due to the growing availability of existing generic treatments, and the trend to adopt Health Economics Outcomes Research (HEOR) assessments is increasing the complexity of clinical research. As a result, the scope of the CRO industry is expanding, and the global market is predicted to value $35bn by 2013.



"Quintiles leads the global CRO market having accrued a market share of 16.9% in 2007, equivalent to sales of $2.7bn..." - Business Insights



Bladerunner

[meixatech]

"4) There is enough of an anatomical rationale to make this more than an act of random desperation."

Perhaps the DARPA trail results played a role in going after SA?

I recall that the DARPA trial with CX717 was designed (Has anyone actually seen the trail protocol used by DARPA?) to allow the subjects to rest (sleep?) during the trial which apparently resulted in failure to show a statistical difference from the controls. Does “rest” mean just watching TV etc. or did the subjects actually sleep? On the other hand, I recall discussions that CX717 causes insomnia. Can this discrepancy (i.e., subjects under the influence of CX717 can sleep when desired) be explained by the dosage of CX717 used in the DARPA trial is low enough to allow the subjects to sleep during the trial?